2021 Annual Meeting Biologics Access Pass-The Business of OrthoBiologics in Clinical Practice

The Business of OrthoBiologics in Clinical Practice

Video Transcription

Video Summary

The speaker highlights orthobiologics as a rapidly growing $4.5-$10 billion global market addressing increasing osteoarthritis cases. These treatments appeal to patients seeking alternatives to total joint replacement and present a valuable business opportunity. Reimbursement is complex, with varied insurance coverage and most services considered experimental, often requiring advanced beneficiary notifications (ABNs) for billing. Coding guidance includes use of codes for VSCO, PRP (0232T), BMAC, and adipose tissue (20999), though many treatments remain cash-pay, non-covered services. Successful practices treat orthobiologics as ancillary services, emphasizing transparency, regulatory compliance, outcome tracking, and ethical patient communication.

Asset Caption

Dr. Louis McIntyre

Keywords

orthobiologics

osteoarthritis treatment

joint replacement alternatives

medical billing codes

patient communication